graft versus host disease (GVHD) | Page 3 | Aplastic Anemia & MDS International Foundation Return to top.

graft versus host disease (GVHD)

Mary K. Hughes, MS, RN, CNS, CT

Hughes, Mary
Outpatient, Clinical Nurse Specialist
University of Texas MD Anderson Cancer Center

Mary K. Hughes, MS, RN, CNS, CT, is a Outpatient, Clinical Nurse Specialist with the University of Texas MD Anderson Cancer Center Psychiatry Department where she works with a team of mental health professionals to support patients, families and caregivers from diagnosis to treatment to survivorship. 

2020 National Virtual Patient & Family Conference

AAMDSIF hosted the 2020 National Patient & Family Conference ONLINE over three days, July 17 - 19, 2020. The Conference featured three days of educational workshops, panels and speakers for patients, families and caregivers with

Event Date: 
Fri, 07/17/2020 (All day) to Sun, 07/19/2020 (All day)

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

Hematopoietic cell transplantation (HCT) is an established therapeutic modality for high risk hematological malignancies in adults and children. The primary cause of morbidity and mortality after HCT is graft versus host disease (GVHD), affecting up to 70% of patients even with current prophylaxis and directly accounting for approximately a third of regimen-related death. Currently, pharmacologic prophylaxis consists of a calcineurin inhibitor and methotrexate, a drug combination introduced around 40 years ago.

CD24Fc for the Prevention of Acute GVHD Following Myeloablative HSCT (CATHY)

The study is designed as a randomized, placebo-controlled, double blind, multicenter, phase III trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX) versus placebo/tacrolimus / methotrexate (placebo/Tac/MTX) in the setting of myeloablative conditioning (MAC), matched

2020 Patient & Family Spring Virtual Conference

About

Due to the coronavirus (COVID-19) pandemic, AAMDSIF made the decision to move our conferences online in order to protect the health of our patients, families, caregivers and faculty.

We would like to acknowledge the support of our many generous patients, families and caregivers as well as our corporate partners including Celgene, Alexion, Novartis, Genentech, Jazz Pharmaceuticals, Apellis and Acceleron.

Event Date: 
Sat, 04/25/2020 (All day)
Conference Event Type: 

National March for Marrow 2020 - Virtual Walk/5K

We've gone VIRTUAL!
With the health and well-being of our patients, family members, friends and faculty as our top priority, AAMDSIF is holding our National March for Marrow as a VIRTUAL WALK! 

Event Date: 
Sat, 07/18/2020 (All day)
Community Event Type: 

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Background:

2019 Patient & Family Conference (Jacksonville, Florida)

AAMDSIF in partnership with the Mayo Clinic Jacksonville hosted our final

Event Date: 
Sat, 11/16/2019 -
12:30pm to 5:30pm
Conference Event Type: 
Share with addtoany.com.